Retinal gene therapy for X-linked retinoschisis showed that AAV8 treatment had positive safety and tolerability outcomes
Researchers at the NIH, National Eye Institute, Bethesda have reported a phase I/IIa study on the use of an AAV8 vector for ocular gene delivery for the treatment of X-linked juvenile retinoschisis (XLRS). While the small 9-patient study was focused on safety and tolerability, one participant in the trial provided the first signal of possible […]Read full story
A progression of Stargardt disease can assess autofluorescence over a 12-month clinical research study.
Researchers at the Institute of Molecular and Clinical Ophthalmology Basel, Switzerland (a consortium led by the ProgStar Study Group) have reported that autofluorescence imaging in Stargardt disease has been used as a monitoring tool over a 12-month period. Outcome measures for interventional clinical trials aimed to slow pathology and progression of the disease are related […]Read full story
A systematic review of registered trials in ClinicalTrials.gov shows the characteristics of geographic atrophy treatment trials
Researchers at the Scheie Eye Institute, University of Pennsylvania, Philadelphia, has published a systematic review to assess the key design characteristics of geographic atrophy (GA) clinical trials, identified in the ClinicalTrials.gov database. In the analysis, the studies comprised a large variation in the design characteristics of the treatment trials. The most common primary outcome measure […]Read full story